The Long Term Impact of Initiating Pramipexole Versus Levodopa in Early Parkinson's Disease (CALM-PD Cohort Study)

University of Rochester222 enrolled

Overview

To determine the long-term consequences (8 years) of initiating patients with Parkinson's disease on either pramipexole or levodopa. We hypothesize that patients initiating therapy with pramipexole compared with levodopa will demonstrate less self-reported disability as measured by the Modified Schwab and England (S/E) scale 8 years after randomization.

Study Type

OBSERVATIONAL

Enrollment

222

Conditions

Parkinson's Disease

Interventions

No intervention.OTHER

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Available 301 subjects enrolled in the CALM-PD study. Exclusion Criteria: * Those not enrolled in the CALM-PD study.

Locations (1)

University of Rochester

Rochester, New York, United States

Outcomes

Primary Outcomes

We hypothesize that patients initiating therapy with pramipexole compared with levodopa will demonstrate less self-reported disability as measured by the Modified Schwab and England.

Time frame: 8 years from date randomized in CALM study

Secondary Outcomes

Our secondary specific aim is to develop and estimate a structural model that will allow us to uncover the causal pathways through which treatments effect outcomes.

Time frame: 8 years from randomization of CALM-PD study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.